Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 11
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
MET exon 14 skipping
pancreatic cancer · Therapy Not Normalized
MET exon 14 skipping is flagged as manual review required because public trials show inclusion required evidence in 15 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT06387342 | https://clinicaltrials.gov/study/NCT02166255 | https://clinicaltrials.gov/study/NCT02427841 | https://clinicaltrials.gov/study/NCT07319416 | https://clinicaltrials.gov/study/NCT06715839 | https://clinicaltrials.gov/study/NCT07649928 | https://clinicaltrials.gov/study/NCT04493060 | https://clinicaltrials.gov/study/NCT06958328 | https://clinicaltrials.gov/study/NCT07627711 | https://clinicaltrials.gov/study/NCT07480928 | https://clinicaltrials.gov/study/NCT06770439 | https://clinicaltrials.gov/study/NCT07066995 | https://clinicaltrials.gov/study/NCT05911217 | https://clinicaltrials.gov/study/NCT04966143 | https://clinicaltrials.gov/study/NCT07039526